Baseline PRO Scores
| PRO | Risankizumab (150 mg) | Placebo |
| SF-36, mean±SD | n=224 | n=219 |
| Physical functioning | 36.0±9.4 | 35.8±9.8 |
| Role physical | 37.3±9.2 | 37.0±9.1 |
| Bodily pain | 36.9±7.4 | 36.3±7.9 |
| General health | 40.0±9.7 | 39.4±9.4 |
| Vitality | 41.4±10.3 | 41.4±9.9 |
| Social functioning | 40.7±10.4 | 40.4±10.8 |
| Role emotional | 42.4±11.2 | 41.5±12.3 |
| Mental health | 43.6±11.1 | 44.3±10.9 |
| PCS | 35.6±8.8 | 35.2±9.1 |
| MCS | 45.3±11.7 | 45.3±11.7 |
| FACIT-Fatigue, mean±SD | n=224 28.2±11.5 | n=219 27.7±12.7 |
| EQ-5D-5L index, mean±SD | n=224 0.64±0.23 | n=219 0.63±0.22 |
| EQ-5D-5L VAS, mean±SD | n=224 56.1±22.2 | n=219 54.2±22.4 |
| Pain VAS, mean±SD | n=224 55.0±23.5 | n=219 57.0±23.1 |
| PtGA VAS, mean±SD | n=224 56.2±21.8 | n=219 56.2±23.0 |
| WPAI (0%–100%), mean±SD | ||
| Overall work impairment* | n=127 47.4±28.9 | n=136 50.1±27.6 |
| Activity impairment | n=224 50.5±26.6 | n=219 51.6±25.7 |
| Absenteeism* | n=127 12.4±24.1 | n=136 11.8±23.5 |
| Presenteeism* | n=123 41.3±26.0 | n=131 45.1±24.2 |
*Reported only for patients who were employed.
EQ-5D-5L, EuroQoL-5 Dimension-5 Level; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy—Fatigue; MCS, mental component summary; PCS, physical component summary; PRO, patient-reported outcome; PtGA, patient’s global assessment of disease activity; SF-36, 36-Item Short-Form Health Survey; VAS, visual analogue scale; WPAI, Work Productivity and Activity Impairment.